Trial Profile
An open-label, prospective, single-centre, phase II study to assess dose and dose interval requirements with respect to efficacy and safety of AOP2014, PEG-Proline-Interferon alpha-2b, in patients with primary myelofibrosis (grade MF-0 and MF-1)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2019
Price :
$35
*
At a glance
- Drugs Ropeginterferon alfa-2b (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Status changed from recruiting to completed as per results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 02 Sep 2014 New trial record